Evolus, Inc. (NASDAQ:EOLS - Get Free Report)'s stock price was down 6.2% during trading on Thursday . The stock traded as low as $16.37 and last traded at $16.37. Approximately 203,467 shares traded hands during trading, a decline of 65% from the average daily volume of 585,329 shares. The stock had previously closed at $17.45.
Wall Street Analyst Weigh In
Several equities analysts recently weighed in on the stock. HC Wainwright restated a "buy" rating and issued a $27.00 price objective on shares of Evolus in a report on Thursday, October 3rd. Barclays raised their price target on Evolus from $16.00 to $20.00 and gave the stock an "overweight" rating in a research report on Friday, September 13th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Evolus in a report on Monday, September 16th. Finally, Needham & Company LLC restated a "buy" rating and set a $22.00 target price on shares of Evolus in a report on Friday, September 13th.
Check Out Our Latest Research Report on EOLS
Evolus Stock Down 4.7 %
The company has a current ratio of 2.92, a quick ratio of 2.67 and a debt-to-equity ratio of 6.26. The firm's fifty day moving average price is $15.65 and its 200-day moving average price is $13.41. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -15.97 and a beta of 1.31.
Evolus (NASDAQ:EOLS - Get Free Report) last posted its earnings results on Wednesday, July 31st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.02). The business had revenue of $66.91 million during the quarter, compared to analysts' expectations of $65.06 million. Sell-side analysts predict that Evolus, Inc. will post -0.64 earnings per share for the current year.
Insider Buying and Selling
In related news, CFO Sandra Beaver sold 3,276 shares of the business's stock in a transaction on Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the sale, the chief financial officer now directly owns 148,502 shares of the company's stock, valued at approximately $2,224,559.96. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the transaction, the chief marketing officer now owns 82,375 shares of the company's stock, valued at approximately $1,305,643.75. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Sandra Beaver sold 3,276 shares of the business's stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the sale, the chief financial officer now directly owns 148,502 shares in the company, valued at $2,224,559.96. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.10% of the stock is owned by company insiders.
Hedge Funds Weigh In On Evolus
Several hedge funds have recently modified their holdings of EOLS. Quest Partners LLC acquired a new position in Evolus during the second quarter valued at approximately $43,000. Quarry LP acquired a new stake in shares of Evolus in the 2nd quarter valued at approximately $54,000. Profund Advisors LLC bought a new position in shares of Evolus in the second quarter valued at $130,000. Arizona State Retirement System increased its holdings in Evolus by 9.4% during the second quarter. Arizona State Retirement System now owns 14,603 shares of the company's stock worth $158,000 after buying an additional 1,253 shares during the last quarter. Finally, ProShare Advisors LLC raised its position in Evolus by 9.9% during the first quarter. ProShare Advisors LLC now owns 11,542 shares of the company's stock worth $162,000 after acquiring an additional 1,035 shares in the last quarter. Institutional investors own 90.69% of the company's stock.
Evolus Company Profile
(
Get Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
